Company intelligence / Profile preview
SemBioSys Genetics
Calgary, Alberta, Canadasembiosys.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
SemBioSys demonstrated in a Phase 1/2 clinical trial that its plant-produced biosimilar insulin (SBS-1000) was bioequivalent to humulin. Preclinical development of Apo AI(Milano) was reported. No subsequent advanced clinical or commercial activities; company wound down after failed partnership attempts.[3][4][6]
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Recombinant proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Martek Biosciences CorporationLonza Inc.Arcadia BiosciencesDow AgroSciences (animal vaccine feasibility)Tasly Pharmaceuticals (unconsummated joint venture, terminated 2012)[3][6]
Beyond the preview
Go deeper on SemBioSys Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SemBioSys Genetics.